236 related articles for article (PubMed ID: 18991395)
1. The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors.
Langley DR; Samanta HK; Lin Z; Walker MA; Krystal MR; Dicker IB
Biochemistry; 2008 Dec; 47(51):13481-8. PubMed ID: 18991395
[TBL] [Abstract][Full Text] [Related]
2. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.
Dicker IB; Samanta HK; Li Z; Hong Y; Tian Y; Banville J; Remillard RR; Walker MA; Langley DR; Krystal M
J Biol Chem; 2007 Oct; 282(43):31186-96. PubMed ID: 17715137
[TBL] [Abstract][Full Text] [Related]
3. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM
J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342
[TBL] [Abstract][Full Text] [Related]
4. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
5. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction.
Esposito D; Craigie R
EMBO J; 1998 Oct; 17(19):5832-43. PubMed ID: 9755183
[TBL] [Abstract][Full Text] [Related]
6. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.
Grobler JA; Stillmock K; Hu B; Witmer M; Felock P; Espeseth AS; Wolfe A; Egbertson M; Bourgeois M; Melamed J; Wai JS; Young S; Vacca J; Hazuda DJ
Proc Natl Acad Sci U S A; 2002 May; 99(10):6661-6. PubMed ID: 11997448
[TBL] [Abstract][Full Text] [Related]
7. Hyrtiosal, from the marine sponge Hyrtios erectus, inhibits HIV-1 integrase binding to viral DNA by a new inhibitor binding site.
Du L; Shen L; Yu Z; Chen J; Guo Y; Tang Y; Shen X; Jiang H
ChemMedChem; 2008 Jan; 3(1):173-80. PubMed ID: 17943714
[TBL] [Abstract][Full Text] [Related]
8. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
9. Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML; Ortuso F; Iraci N; De Luca L; Alcaro S; Chimirri A
Biochem Biophys Res Commun; 2007 Nov; 363(3):554-60. PubMed ID: 17889829
[TBL] [Abstract][Full Text] [Related]
10. Single amino acid substitution in HIV-1 integrase catalytic core causes a dramatic shift in inhibitor selectivity.
Al-Mawsawi LQ; Sechi M; Neamati N
FEBS Lett; 2007 Mar; 581(6):1151-6. PubMed ID: 17328897
[TBL] [Abstract][Full Text] [Related]
11. The use of a new in vitro reaction substrate reproducing both U3 and U5 regions of the HIV-1 3'-ends increases the correlation between the in vitro and in vivo effects of the HIV-1 integrase inhibitors.
Tramontano E; Onidi L; Esposito F; Badas R; La Colla P
Biochem Pharmacol; 2004 May; 67(9):1751-61. PubMed ID: 15081874
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).
Gleenberg IO; Herschhorn A; Hizi A
J Mol Biol; 2007 Jun; 369(5):1230-43. PubMed ID: 17490682
[TBL] [Abstract][Full Text] [Related]
13. New approaches for inhibiting HIV integrase: a journey beyond the active site.
Walker MA
Curr Opin Investig Drugs; 2009 Feb; 10(2):129-36. PubMed ID: 19197790
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro.
Deprez E; Barbe S; Kolaski M; Leh H; Zouhiri F; Auclair C; Brochon JC; Le Bret M; Mouscadet JF
Mol Pharmacol; 2004 Jan; 65(1):85-98. PubMed ID: 14722240
[TBL] [Abstract][Full Text] [Related]
15. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors.
Deng J; Lee KW; Sanchez T; Cui M; Neamati N; Briggs JM
J Med Chem; 2005 Mar; 48(5):1496-505. PubMed ID: 15743192
[TBL] [Abstract][Full Text] [Related]
16. Triketoacid inhibitors of HIV-integrase: a new chemotype useful for probing the integrase pharmacophore.
Walker MA; Johnson T; Ma Z; Banville J; Remillard R; Kim O; Zhang Y; Staab A; Wong H; Torri A; Samanta H; Lin Z; Deminie C; Terry B; Krystal M; Meanwell N
Bioorg Med Chem Lett; 2006 Jun; 16(11):2920-4. PubMed ID: 16546383
[TBL] [Abstract][Full Text] [Related]
17. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.
Loizidou EZ; Kousiappa I; Zeinalipour-Yazdi CD; Van de Vijver DA; Kostrikis LG
Biochemistry; 2009 Jan; 48(1):4-6. PubMed ID: 19090674
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles.
Middleton T; Lim HB; Montgomery D; Rockway T; Tang H; Cheng X; Lu L; Mo H; Kohlbrenner WE; Molla A; Kati WM
Antiviral Res; 2004 Oct; 64(1):35-45. PubMed ID: 15451177
[TBL] [Abstract][Full Text] [Related]
19. Influence of Mg2+ on the binding modes of HIV-1 integrase with thiazolothiazepine inhibitor studied by molecular simulation.
Wang L
Comput Biol Med; 2009 Apr; 39(4):355-60. PubMed ID: 19268284
[TBL] [Abstract][Full Text] [Related]
20. Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of action.
Levin A; Benyamini H; Hayouka Z; Friedler A; Loyter A
FEBS J; 2011 Jan; 278(2):316-30. PubMed ID: 21156026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
